Artemisinin-resistant malaria: Research challenges, opportunities, and public health implications

Rick M. Fairhurst, Gaurvika M.L. Nayyar, Joel G. Breman, Rachel Hallett, Jonathan L. Vennerstrom, Socheat Duong, Pascal Ringwald, Thomas E. Wellems, Christopher V. Plowe, Arjen M. Dondorp

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Artemisinin-based combination therapies are the most effective drugs to treat Plasmodium falciparum malaria. Reduced sensitivity to artemisinin monotherapy, coupled with the emergence of parasite resistance to all partner drugs, threaten to place millions of patients at risk of inadequate treatment of malaria. Recognizing the significance and immediacy of this possibility, the Fogarty International Center and the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health convened a conference in November 2010 to bring together the diverse array of stakeholders responding to the growing threat of artemisinin resistance, including scientists from malarious countries in peril. This conference encouraged and enabled experts to share their recent unpublished data from studies that may improve our understanding of artemisinin resistance. Conference sessions addressed research priorities to forestall artemisinin resistance and fostered collaborations between field- and laboratory-based researchers and international programs, with the aim of translating new scientific evidence into public health solutions. Inspired by this conference, this review summarizes novel findings and perspectives on artemisinin resistance, approaches for translating research data into relevant public health information, and opportunities for interdisciplinary collaboration to combat artemisinin resistance.

Original languageEnglish (US)
Pages (from-to)231-241
Number of pages11
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume87
Issue number2
DOIs
StatePublished - Aug 1 2012

Fingerprint

Malaria
Public Health
Research
National Institute of Allergy and Infectious Diseases (U.S.)
Falciparum Malaria
National Institutes of Health (U.S.)
artemisinine
Pharmaceutical Preparations
Parasites
Research Personnel
Therapeutics

ASJC Scopus subject areas

  • Parasitology
  • Virology
  • Infectious Diseases

Cite this

Artemisinin-resistant malaria : Research challenges, opportunities, and public health implications. / Fairhurst, Rick M.; Nayyar, Gaurvika M.L.; Breman, Joel G.; Hallett, Rachel; Vennerstrom, Jonathan L.; Duong, Socheat; Ringwald, Pascal; Wellems, Thomas E.; Plowe, Christopher V.; Dondorp, Arjen M.

In: American Journal of Tropical Medicine and Hygiene, Vol. 87, No. 2, 01.08.2012, p. 231-241.

Research output: Contribution to journalArticle

Fairhurst, RM, Nayyar, GML, Breman, JG, Hallett, R, Vennerstrom, JL, Duong, S, Ringwald, P, Wellems, TE, Plowe, CV & Dondorp, AM 2012, 'Artemisinin-resistant malaria: Research challenges, opportunities, and public health implications', American Journal of Tropical Medicine and Hygiene, vol. 87, no. 2, pp. 231-241. https://doi.org/10.4269/ajtmh.2012.12-0025
Fairhurst, Rick M. ; Nayyar, Gaurvika M.L. ; Breman, Joel G. ; Hallett, Rachel ; Vennerstrom, Jonathan L. ; Duong, Socheat ; Ringwald, Pascal ; Wellems, Thomas E. ; Plowe, Christopher V. ; Dondorp, Arjen M. / Artemisinin-resistant malaria : Research challenges, opportunities, and public health implications. In: American Journal of Tropical Medicine and Hygiene. 2012 ; Vol. 87, No. 2. pp. 231-241.
@article{76c8c4d724704583b88337ea35a8e79c,
title = "Artemisinin-resistant malaria: Research challenges, opportunities, and public health implications",
abstract = "Artemisinin-based combination therapies are the most effective drugs to treat Plasmodium falciparum malaria. Reduced sensitivity to artemisinin monotherapy, coupled with the emergence of parasite resistance to all partner drugs, threaten to place millions of patients at risk of inadequate treatment of malaria. Recognizing the significance and immediacy of this possibility, the Fogarty International Center and the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health convened a conference in November 2010 to bring together the diverse array of stakeholders responding to the growing threat of artemisinin resistance, including scientists from malarious countries in peril. This conference encouraged and enabled experts to share their recent unpublished data from studies that may improve our understanding of artemisinin resistance. Conference sessions addressed research priorities to forestall artemisinin resistance and fostered collaborations between field- and laboratory-based researchers and international programs, with the aim of translating new scientific evidence into public health solutions. Inspired by this conference, this review summarizes novel findings and perspectives on artemisinin resistance, approaches for translating research data into relevant public health information, and opportunities for interdisciplinary collaboration to combat artemisinin resistance.",
author = "Fairhurst, {Rick M.} and Nayyar, {Gaurvika M.L.} and Breman, {Joel G.} and Rachel Hallett and Vennerstrom, {Jonathan L.} and Socheat Duong and Pascal Ringwald and Wellems, {Thomas E.} and Plowe, {Christopher V.} and Dondorp, {Arjen M.}",
year = "2012",
month = "8",
day = "1",
doi = "10.4269/ajtmh.2012.12-0025",
language = "English (US)",
volume = "87",
pages = "231--241",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "2",

}

TY - JOUR

T1 - Artemisinin-resistant malaria

T2 - Research challenges, opportunities, and public health implications

AU - Fairhurst, Rick M.

AU - Nayyar, Gaurvika M.L.

AU - Breman, Joel G.

AU - Hallett, Rachel

AU - Vennerstrom, Jonathan L.

AU - Duong, Socheat

AU - Ringwald, Pascal

AU - Wellems, Thomas E.

AU - Plowe, Christopher V.

AU - Dondorp, Arjen M.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Artemisinin-based combination therapies are the most effective drugs to treat Plasmodium falciparum malaria. Reduced sensitivity to artemisinin monotherapy, coupled with the emergence of parasite resistance to all partner drugs, threaten to place millions of patients at risk of inadequate treatment of malaria. Recognizing the significance and immediacy of this possibility, the Fogarty International Center and the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health convened a conference in November 2010 to bring together the diverse array of stakeholders responding to the growing threat of artemisinin resistance, including scientists from malarious countries in peril. This conference encouraged and enabled experts to share their recent unpublished data from studies that may improve our understanding of artemisinin resistance. Conference sessions addressed research priorities to forestall artemisinin resistance and fostered collaborations between field- and laboratory-based researchers and international programs, with the aim of translating new scientific evidence into public health solutions. Inspired by this conference, this review summarizes novel findings and perspectives on artemisinin resistance, approaches for translating research data into relevant public health information, and opportunities for interdisciplinary collaboration to combat artemisinin resistance.

AB - Artemisinin-based combination therapies are the most effective drugs to treat Plasmodium falciparum malaria. Reduced sensitivity to artemisinin monotherapy, coupled with the emergence of parasite resistance to all partner drugs, threaten to place millions of patients at risk of inadequate treatment of malaria. Recognizing the significance and immediacy of this possibility, the Fogarty International Center and the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health convened a conference in November 2010 to bring together the diverse array of stakeholders responding to the growing threat of artemisinin resistance, including scientists from malarious countries in peril. This conference encouraged and enabled experts to share their recent unpublished data from studies that may improve our understanding of artemisinin resistance. Conference sessions addressed research priorities to forestall artemisinin resistance and fostered collaborations between field- and laboratory-based researchers and international programs, with the aim of translating new scientific evidence into public health solutions. Inspired by this conference, this review summarizes novel findings and perspectives on artemisinin resistance, approaches for translating research data into relevant public health information, and opportunities for interdisciplinary collaboration to combat artemisinin resistance.

UR - http://www.scopus.com/inward/record.url?scp=84864883641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864883641&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.2012.12-0025

DO - 10.4269/ajtmh.2012.12-0025

M3 - Article

C2 - 22855752

AN - SCOPUS:84864883641

VL - 87

SP - 231

EP - 241

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 2

ER -